Short summary

This study is designed to evaluate the efficacy of the current follow-up programme regarding FDG-PET/CT scans of patients treated with adjuvant immunotherapy following radical resection of high risk melanoma.

Rationale

Since the fall of 2018, Danish patients with high-risk melanoma have been offered adjuvant immunotherapy after radical surgery, in order to reduce the risk of recurring disease. The patients who opt for the adjuvant immunotherapy are enrolled in an follow-up programme which consists of control scans 4 times during the first year after surgery. We seek to evaluate the diagnostic validity of these scans.

Description of the cohort

Patients with high-risk melanoma (IIb+c, III or IV), recieving immunotherapy after radical surgery, treated at OUH, Denmark.

Data and biological material

Pathology data:

Pathology data provided initial diagnosis and staging, as well as recurrent disease diagnosis.

Patient record data:

Patient records from OUH provided data on the number of treatments patients recieved, scan-results, reasons for stopping treatment and outcome.

Registry data:

Danish Melanoma Database provided data on patients with the relevant diagnosis and stage of disease.

Collaborating researchers and departments

Department of Nuclear Medicine, Odense University Hospital

• Stud. Med. Jesper Alexander Sommer Andersen
• Stud. Med. Anders Dyhr Spatzek
• MD, Associate Professor Peter Grupe
• MD, Mie Vilstrup

Department of Oncology, Odense University Hospital

• MD, Lars Bastholt